

## Special Issue

# Novel Approaches for the Treatment of Antimicrobial-Resistant Pathogens

### Message from the Guest Editor

Antimicrobial resistance is a significant problem in humans and animals worldwide. The extensive and non-selective use of antibiotics has resulted in the rise of bacteria that are resistant to antimicrobial agents, hence limiting the available treatment options for multidrug-resistant bacterial infections. To control antimicrobial resistance (AMR), it is imperative to engage in the systematic surveillance of AMR infection dissemination. Furthermore, there is an urgent need to identify and develop novel strategies that can control antimicrobial-resistant pathogens. These approaches include, but are not limited to, probiotics, prebiotics, antivirulence and quorum sensing inhibitors, small molecules, peptides, essential oils, nanoparticles and vaccines. This Special Issue welcomes high-quality original research papers on topics related to antibiotic alternatives.

### Guest Editor

Dr. Yosra A. Helmy

Department of Veterinary Science, University of Kentucky, Lexington, KY 40504, USA

### Deadline for manuscript submissions

closed (31 July 2025)



## Antibiotics

an Open Access Journal  
by MDPI

Impact Factor 4.6  
CiteScore 8.7  
Indexed in PubMed



[mdpi.com/si/190015](https://mdpi.com/si/190015)

*Antibiotics*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[antibiotics@mdpi.com](mailto:antibiotics@mdpi.com)

[mdpi.com/journal/  
antibiotics](https://mdpi.com/journal/antibiotics)





# Antibiotics

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.6  
CiteScore 8.7  
Indexed in PubMed



[mdpi.com/journal/  
antibiotics](https://mdpi.com/journal/antibiotics)



## About the Journal

### Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

---

### Editor-in-Chief

Prof. Dr. Nicholas Dixon  
School of Chemistry and Molecular Bioscience, University of  
Wollongong, Wollongong, NSW 2522, Australia

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)